1Klein R, Klein BE, Moss SE,et al. The Wisconsin epidemiologic study of diabetic retinopathy. Ⅲ. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years [ J ]. Arch Ophthalmol, 1984,102 (4) : 527 - 532.
2The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[ J ]. N Engl J Med, 1993,329 (14) :977 - 986.
3UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J]. Lancet, 1998,352(9131 ) :837 -853.
4Dornan TL, Ting A, McPherson CK,et al. Genetic susceptibility to the development of retinopathy in insulin-dependent diabetics [ J ]. Diabetes, 1982,31 (3) :226 -231.
5Leslie RD, Pyke DA. Diabetic retinopathy in identical twins[ J]. Diabetes, 1982,31 ( 1 ) :19 -21.
7Danser AH, Derkx FH, Admiraal PJ,et al. Angiotensin levels in the eye[ J ]. Invest Ophthalmol Vis Sci, 1994,35 (3) : 1008 - 1018.
8Vitale S. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: what can we learn at 14 years[ J ] ? Ophthalmology, 1998,105 (10) :1799 - 1800.
9Fong DS, Ferris FL 3rd, Davis MD, et al. Causes of severe visual loss in the early treatment diabetic retinopathy study : ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Grouo [ J ]. Am J Ophthalmol, 1999,127 (2) : 137 - 141.
10Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type Ⅱ diabetes over 6 years from diagnosis[ J ]. Diabetologia, 2001,44 (2) : 156 - 163.
2Nishimura C, Saito T, Tanimoto T. High levels of erythroeyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia, 1994, 37: 328-330.
3Ellis EA, Guberski DL, Hutson B, et al. Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/WOR rat. Nitric Oxide, 2002, 6:295-304.
4Hanmes HP, Alt A, Niwa T, et al. Diferential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabet ologia, 1999,42 : 728-736.
5Handa JT, Verzijl N, Matsunaga H, et al. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. lnvest Ophthalmol Vis Sci,1999,40:775-779.
6Chibber R, Molinatti PA, Rosatto N, et al. Toxic action of advanced glycation end products on cultured retinal capilary pericytes and endothelial cells..relevance to diabetic retinopathy. Diabetologia, 1997,40 :156-164.
7Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol, 2002,86:363-365.
8Miyahara S, Kiryu J, Yamashiro K, et al. Simvastatin inhibits leukoeyte aeeumulation and vaseular permeability in the retinas of rats with streptozotoein-indueed diabetes. Am J Pathol, 2004,164:1697- 1706.
9Joussen AM,Poulaki V, Le ML, et al. The central role for inflammation in the pathogenesis of diabetic retinopathy. FASEBJ, 2004,18:1450-1452.
10Barber AJ. A new view of diabetic retinopathy:a neurodegenerative disease of the eye. Progress in neuropsychopharmacology & biological psychiatry, 2003 , 27, 283- 290.
